贲门神经内分泌癌1例并文献复习
A Case of Neuroendocrine Carcinoma of the Gastroesophageal Junction and Literature Review
DOI: 10.12677/acm.2025.153692, PDF,   
作者: 田 娇：青岛大学青岛医学院，山东 青岛；张红军*：青岛大学附属医院肿瘤放疗科，山东 青岛
关键词: 贲门癌；神经内分泌癌；靶向治疗；免疫治疗；临床病理特征；Gastroesophageal Junction Cancer； Neuroendocrine Carcinoma； Targeted Therapy； Immune Therapy； Clinicopathologic Features
摘要: 目的：对1例贲门神经内分泌癌病例进行报道，探讨该病的治疗方案，以期有助于提高对该疾病的疗效。方法：对我院收治的1例贲门神经内分泌癌的诊疗过程的病例资料进行总结，并结合相关文献进行分析。结果：该贲门神经内分泌癌患者经手术、术后辅助放、化疗，疾病进展后更换化疗方案、加用靶向治疗及免疫治疗，现患者病情稳定门诊随访中。
Abstract: Objective: To report a case of gastroesophageal junction neuroendocrine carcinoma and explore treatment options for the disease, with the aim of improving therapeutic outcomes. Method: The diagnostic and treatment process of a gastroesophageal junction neuroendocrine carcinoma case treated in our hospital was summarized and analyzed in combination with relevant literature. Result: The patient underwent surgery, followed by adjuvant radiotherapy and chemotherapy. After disease progression, the treatment regimen was changed, with the addition of targeted therapy and immunotherapy. The patient’s condition is currently stable, and the patient is undergoing regular outpatient follow-up.
文章引用：田娇, 张红军. 贲门神经内分泌癌1例并文献复习[J]. 临床医学进展, 2025, 15(3): 885-891. https://doi.org/10.12677/acm.2025.153692

参考文献

[1] Rizen, E.N. and Phan, A.T. (2022) Neuroendocrine Tumors: A Relevant Clinical Update. Current Oncology Reports, 24, 703-714. [Google Scholar] [CrossRef] [PubMed]
[2] 李增山. 胃肠胰神经内分泌肿瘤分类及病理学进展[J]. 浙江大学学报(医学版), 2016, 45(1): 10-23.
[3] Thomaz Araújo, T.M., Barra, W.F., Khayat, A.S. and de Assumpção, P.P. (2017) Insights into Gastric Neuroendocrine Tumors Burden. Chinese Journal of Cancer Research, 29, 137-143. [Google Scholar] [CrossRef] [PubMed]
[4] 梁文全, 张旺, 乔屾, 等. 240例胃神经内分泌肿瘤的临床病理特征及预后分析[J]. 中华胃肠外科杂志, 2020, 23(1): 38-43.
[5] Lawrence, B., Gustafsson, B.I., Chan, A., Svejda, B., Kidd, M. and Modlin, I.M. (2011) The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors. Endocrinology and Metabolism Clinics of North America, 40, 1-18. [Google Scholar] [CrossRef] [PubMed]
[6] Yang, Z., Wang, W., Lu, J., Pan, G., Pan, Z., Chen, Q., et al. (2018) Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend toward Improved Survival. Cellular Physiology and Biochemistry, 45, 389-396. [Google Scholar] [CrossRef] [PubMed]
[7] 中国抗癌协会神经内分泌肿瘤专业委员会. 中国抗癌协会神经内分泌肿瘤诊治指南(2022年版) [J]. 中国癌症杂志, 2022, 32(6): 545-580.
[8] Nagtegaal, I.D., Odze, R.D., Klimstra, D., Paradis, V., Rugge, M., Schirmacher, P., et al. (2019) The 2019 WHO Classification of Tumours of the Digestive System. Histopathology, 76, 182-188. [Google Scholar] [CrossRef] [PubMed]
[9] 2013年中国胃肠胰神经内分泌肿瘤病理诊断共识专家组. 中国胃肠胰神经内分泌肿瘤病理诊断共识(2013版) [J]. 中华病理学杂志, 2013, 42(10): 691-694.
[10] Liu, J., Pan, X., Sun, Y., Dong, T., Hu, X., Zhong, H., et al. (2022) Clinicopathological Features and Postoperative Survival Analysis of Gastric Carcinoma with Neuroendocrine Differentiation. Journal of Oncology, 2022, 1-9. [Google Scholar] [CrossRef] [PubMed]
[11] Wang, R., Liu, H., Liang, P., Zhao, H., Li, L. and Gao, J. (2021) Radiomics Analysis of CT Imaging for Differentiating Gastric Neuroendocrine Carcinomas from Gastric Adenocarcinomas. European Journal of Radiology, 138, Article 109662. [Google Scholar] [CrossRef] [PubMed]
[12] Kim, S.H., Kim, S.H., Kim, M., Shin, C., Han, J.K. and Choi, B.I. (2015) CT Differentiation of Poorly-Differentiated Gastric Neuroendocrine Tumours from Well-Differentiated Neuroendocrine Tumours and Gastric Adenocarcinomas. European Radiology, 25, 1946-1957. [Google Scholar] [CrossRef] [PubMed]
[13] 方成, 王玮, 张雨, 等. 中国南方多中心胃神经内分泌癌临床病理特征及预后分析[J]. 中华胃肠外科杂志, 2016, 19(11): 1230-1234.
[14] Sandvik, O.M., Søreide, K., Gudlaugsson, E., Kvaløy, J.T. and Søreide, J.A. (2016) Epidemiology and Classification of Gastroenteropancreatic Neuroendocrine Neoplasms Using Current Coding Criteria. Journal of British Surgery, 103, 226-232. [Google Scholar] [CrossRef] [PubMed]
[15] Delle Fave, G., O’Toole, D., Sundin, A., Taal, B., Ferolla, P., Ramage, J.K., et al. (2016) ENETS Consensus Guidelines Update for Gastroduodenal Neuroendocrine Neoplasms. Neuroendocrinology, 103, 119-124. [Google Scholar] [CrossRef] [PubMed]
[16] Thornblade, L.W., Warner, S.G., Melstrom, L., Ituarte, P.H.G., Chang, S., Li, D., et al. (2021) Does Surgery Provide a Survival Advantage in Non-Disseminated Poorly Differentiated Gastroenteropancreatic Neuroendocrine Neoplasms? Surgery, 169, 1417-1423. [Google Scholar] [CrossRef] [PubMed]
[17] Zhang, P., Li, J., Li, J., Zhang, X., Zhou, J., Wang, X., et al. (2020) Etoposide and Cisplatin versus Irinotecan and Cisplatin as the First-Line Therapy for Patients with Advanced, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinoma: A Randomized Phase 2 Study. Cancer, 126, 2086-2092. [Google Scholar] [CrossRef] [PubMed]
[18] Du, Z., Wang, Y., Zhou, Y., Wen, F. and Li, Q. (2013) First-line Irinotecan Combined with 5-Fluorouracil and Leucovorin for High-Grade Metastatic Gastrointestinal Neuroendocrine Carcinoma. Tumori Journal, 99, 57-60. [Google Scholar] [CrossRef] [PubMed]
[19] Walter, T., Lievre, A., Coriat, R., Malka, D., Elhajbi, F., Di Fiore, F., et al. (2023) Bevacizumab plus FOLFIRI after Failure of Platinum-Etoposide First-Line Chemotherapy in Patients with Advanced Neuroendocrine Carcinoma (PRODIGE 41-BEVANEC): A Randomised, Multicentre, Non-Comparative, Open-Label, Phase 2 Trial. The Lancet Oncology, 24, 297-306. [Google Scholar] [CrossRef] [PubMed]
[20] Chan, D.L., Bergsland, E.K., Chan, J.A., Gadgil, R., Halfdanarson, T.R., Hornbacker, K., et al. (2021) Temozolomide in Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Retrospective Review. The Oncologist, 26, 950-955. [Google Scholar] [CrossRef] [PubMed]
[21] Thomas, K., Voros, B.A., Meadows-Taylor, M., Smeltzer, M.P., Griffin, R., Boudreaux, J.P., et al. (2020) Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs). Cancers, 12, Article 206. [Google Scholar] [CrossRef] [PubMed]
[22] Sansovini, M., Severi, S., Ambrosetti, A., Monti, M., Nanni, O., Sarnelli, A., et al. (2013) Treatment with the Radiolabelled Somatostatin Analog 177lu-Dotatate for Advanced Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 97, 347-354. [Google Scholar] [CrossRef] [PubMed]
[23] Sabet, A., Dautzenberg, K., Haslerud, T., Aouf, A., Sabet, A., Simon, B., et al. (2015) Specific Efficacy of Peptide Receptor Radionuclide Therapy with 177lu-Octreotate in Advanced Neuroendocrine Tumours of the Small Intestine. European Journal of Nuclear Medicine and Molecular Imaging, 42, 1238-1246. [Google Scholar] [CrossRef] [PubMed]
[24] Lu, M., Zhang, P., Zhang, Y., Li, Z., Gong, J., Li, J., et al. (2020) Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase IB Trial. Clinical Cancer Research, 26, 2337-2345. [Google Scholar] [CrossRef] [PubMed]
[25] Patel, S.P., Othus, M., Chae, Y.K., Giles, F.J., Hansel, D.E., Singh, P.P., et al. (2020) A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clinical Cancer Research, 26, 2290-2296. [Google Scholar] [CrossRef] [PubMed]
[26] Yao, J.C., Shah, M.H., Ito, T., Bohas, C.L., Wolin, E.M., Van Cutsem, E., et al. (2011) Everolimus for Advanced Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 364, 514-523. [Google Scholar] [CrossRef] [PubMed]
[27] Xu, J., Shen, L., Bai, C., Wang, W., Li, J., Yu, X., et al. (2020) Surufatinib in Advanced Pancreatic Neuroendocrine Tumours (SANET-P): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 21, 1489-1499. [Google Scholar] [CrossRef] [PubMed]
[28] Xu, J., Shen, L., Zhou, Z., Li, J., Bai, C., Chi, Y., et al. (2020) Surufatinib in Advanced Extrapancreatic Neuroendocrine Tumours (SANET-EP): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study. The Lancet Oncology, 21, 1500-1512. [Google Scholar] [CrossRef] [PubMed]

为你推荐